<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962269</url>
  </required_header>
  <id_info>
    <org_study_id>M2019176</org_study_id>
    <nct_id>NCT04962269</nct_id>
  </id_info>
  <brief_title>Application of DWI in Diagnosis of Prostate Cancer</brief_title>
  <official_title>Different Models of Multiple B-value DWI and Their Applications in Diagnosis of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the performance of different models of multiple b-value DWI in diagnosing&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffusion weighted imaging (DWI) plays an important role in the diagnosis and stratification&#xD;
      of prostate cancer. Traditional DWI apply the apparent diffusion coefficient (ADC) to reflect&#xD;
      the diffusion of tissue water, which is a parameter calculated by a monoexponential model&#xD;
      with 2b values. In recent years, the development of multiple b-value DWI facilitates the&#xD;
      appearance of many new mathematical models. Different models have different features, but&#xD;
      their value of applications in prostate cancer still need to be confirmed. This study was&#xD;
      aiming to: (1) compare the parameters derived from monoexponential model, intravoxel&#xD;
      incoherent motion (IVIM) model and stretched exponential model between prostate cancer and&#xD;
      benign prostatic hyperplasia; (2) compare the difference of these parameters between&#xD;
      low-grade (Gleason score ≤ 3+4) and high-grade (Gleason score ≥ 4+3) cancer; (3) find whether&#xD;
      these parameters derived from new models are superior to ADC derived from traditional&#xD;
      monoexponetial model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2013</start_date>
  <completion_date type="Actual">June 21, 2018</completion_date>
  <primary_completion_date type="Actual">June 21, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pathological diagnosis</measure>
    <time_frame>2013.10-2018.6</time_frame>
    <description>prostate cancer or benign prostatic hyperplasia</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">103</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>prostate cancer</arm_group_label>
    <description>The patient was pathologically diagnosed with prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign prostatic hyperplasia</arm_group_label>
    <description>The patient was pathologically diagnosed with benign prostatic hyperplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model</description>
    <arm_group_label>prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with prostatic diseases confirmed as prostate cancer or benign prostatic&#xD;
        hyperplasia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The exam including T1WI、T2WI and multiple b-value DWI.&#xD;
&#xD;
          2. Comfired by pathology as prostate cancer or benign prostatic hyperplasia in one month&#xD;
             after the MRI exam.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.No Gleason score data. 2.Awful quality of imagings or artifacts affectting&#xD;
             diagnosis. 3.No lesion larger than 0.5cm. 4.Any surgery or treatment before MRI exam.&#xD;
             5.Biopsy in 4 weeks before MRI exam.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianyu Liu</last_name>
    <role>Study Director</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>benign prostatic hyperplasia</keyword>
  <keyword>Diffusion weighted imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

